Interleukin 2: prototype for a new generation of immunoactive pharmaceuticals. Review uri icon

Overview

abstract

  • Molecular biological techniques have revealed the interleukin-2 receptor to be a dimer composed of one alpha-subunit and one beta-subunit which interact noncovalently in a cooperative manner. Site-directed mutagenesis, in conjunction with structural analysis, is beginning to clarify the relationship between structural components of the receptor and their function, and Thomas Ciardelli and Kendall Smith explain why this is bringing drug developers closer to the design of IL-2 agonists and antagonists.

publication date

  • June 1, 1989

Research

keywords

  • Adjuvants, Immunologic
  • Interleukin-2
  • Receptors, Interleukin-2

Identity

Scopus Document Identifier

  • 0024402112

Digital Object Identifier (DOI)

  • 10.1016/0165-6147(89)90269-1

PubMed ID

  • 2672465

Additional Document Info

volume

  • 10

issue

  • 6